ArticleBrain and behavior2018
Clinical characteristics and quality of life in Chinese patients with multiple system atrophy.
Article in Brain and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- A Systematic Review of the Spectrum and Prevalence of Non-motor Symptoms in Multiple System Atrophy.Cerebellum (London, England) · 2024Pooled it
- Assessments scales for the evaluation of health-related quality of life in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a systematic review.Frontiers in psychology · 2024Pooled it
- Natural history and 12-month progression of multiple system atrophy in a Chinese cohort.BMC neurology · 2026Observational
- Locus coeruleus neuromelanin, cognitive dysfunction, and brain metabolism in multiple system atrophy.Journal of neurology · 2025Article
- A Review on the Clinical Diagnosis of Multiple System Atrophy.Cerebellum (London, England) · 2023Review
- Neurological update: non-motor symptoms in atypical parkinsonian syndromes.Journal of neurology · 2023Article
- Neurological update: the palliative care landscape for atypical parkinsonian syndromes.Journal of neurology · 2023Article
- Factors impacting quality of life in multiple system atrophy.Frontiers in neurology · 2023Article
- Health-related quality of life in patients with multiple system atrophy using the EQ-5D-5L.Brain and behavior · 2022Article
- Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism.Journal of clinical neurology (Seoul, Korea) · 2022Review
- Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy.Frontiers in neurology · 2022Article
- Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects.Frontiers in psychiatry · 2022Review
- Clinical characteristics and quality of life in Chinese patients with multiple system atrophy.Brain and behavior · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMultiple system atrophy (MSA) is a progressive neurodegenerative disorder that causes early sustained disability and poor health-related quality of life (HrQoL). The clinical features and their effects on the HrQoL of patients in China have received little attention in the research literature. We evaluated the clinical characteristics and HrQoL of Chinese patients with MSA. MATERIALS AND
methodsA total of 143 patients with MSA from the Department of Neurology, Shanghai Ruijin Hospital, were enrolled in the study from March 2014 to May 2017. Basic demographic data, motor symptoms, non-motor symptoms, and HrQoL were assessed and compared with data from 198 patients with idiopathic Parkinson's disease (PD) who were matched by age, gender, and disease duration. Factors influencing the HrQoL of MSA patients were also analyzed.
resultsThe ratio of patients with predominant parkinsonism (MSA-P) and prominent cerebellar ataxia (MSA-C) was 95:48 among the 143 MSA patients. MSA-P patients had a longer disease duration (p = 0.002), higher levodopa equivalent daily dose (p < 0.001), higher scores on the Unified Multiple System Atrophy Rating Scale (UMSARS) I (p = 0.026), UMSARS II (p < 0.001), UMSARS IV (p = 0.019), the Hamilton Rating Scale for Depression (p = 0.001), the Hamilton Anxiety Scale (p = 0.013), and lower scores on measures of olfaction (p = 0.021) and cognitive function (p = 0.044) than the MSA-C patients. Stepwise regression analysis showed that depression, anxiety, degree of disability, and disease severity were independent predictors of decreased HrQoL.
conclusionsThe results indicate that MSA-P patients have more severe motor impairment, hyposmia, depression, anxiety, cognitive impairment, and lower HrQoL than MSA-C patients. Depression, anxiety, degree of disability, and disease severity are predictors of poor HrQoL among Chinese patients with MSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.